Atom Therapeutics
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | NLRP3 inflammasomeSmall molecule | Atherosclerotic Cardiovascular Disease | |
| Phase 2 | URAT1 (urate transporter 1, SLC22A12)Small molecule | Chronic Kidney Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
October 2027 (1)
Est. primary completion 2027-10-31 · NCT07323095 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
8 September 2025Topline resultLingdolinurad (ABP-671)Positive topline results from the global Phase 2b/3 trial of lingdolinurad (ABP-671) in chronic gout
Atom Therapeutics · Source ↗
Financial reports
No financial reports recorded.